GlaxoSmithKline PLC (GSK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

GlaxoSmithKline PLC (GSK)

51.98

+0.63 (1.23%)

as of Jul 27, 2026, 8:00:00 pm Market Open.

82 watching

Investor Insights

Jul 27, 2026, 12:00 am

This summary was created by AI, based on 4 opinions in the last 12 months.

GlaxoSmithKline PLC (GSK) has received positive feedback from Stockchase Research Editor Michael O'Reilly, with multiple top picks highlighting significant gains in the stock's performance. The reviews indicate that GSK has been progressing well and suggests maintaining disciplined trading strategies by adjusting stop-loss levels upwards—reflecting confidence in the company's trajectory, particularly regarding their recent performance. However, some concerns linger within their vaccine division due to general skepticism surrounding vaccines in the U.S. market. Despite this, only a third of GSK's business is tied to vaccines, implying a diversified revenue stream that may mitigate the impact of vaccine-related dismay over time. Additionally, ongoing trials have the potential to position GSK favorably against competitors in the drug market, although it's expected that sentiment around their vaccine business may take time to improve.

Consensus

Positive

Valuation

Fair Value

Similar

Merck,MRK

TOP PICK

Growth in revenue, earnings, cash flow and earnings per share shall not better than its peers. Stable of products is very, very good. Good dividend.

BUY

Likes the pharmaceutical sector. The whole pharmaceutical area is cheap. Has a good pipeline. Pays a good dividend. Cheap. Well run.

DON'T BUY

A lot of trouble with these companies is having access to new products. They are so large now they have to continually feed the pipeline at an accelerated rate by acquiring at higher prices.

PAST TOP PICK

(A Top Pick May 8/06. Down 4%.) Pays at 3.5% dividend.

TOP PICK

Have increased the products in their pipeline. AA credit. 3.5% yield. Good long-term outlook.

BUY

5% dividend. The European pharmaceuticals have been in better shape generally than their US counterparts, so they are probably a better value story than this one. They’re looking to acquire to help their drug pipeline.

BUY

The 2nd largest pharmaceutical supplier globally. They also have good health care as well. Have an excellent pipeline, good dividend and good management.

BUY

Buying it now for 2005/2006 because, looking down the road, they are getting a 3.5/4% yield. A great way to play India.

Wealthica Track your Stocks in your Watch List

TOP PICK

Dividend yield of more than 5%. They have a major portion of the pharmaceutical industry in India. May have to be patient.

WEAK BUY

They don't have a great pipeline. Have good profit margins on some vaccines and AIDS medications. The price is decent.

BUY

Likes, but prefers Johnson & Johnson.

BUY

Will take a few years for their products to come through, but you are getting a free cash flow yield of about 12%.

BUY

Prefers over US pharmaceuticals. Better situated globally.

TOP PICK

Good value. Yield of 2.3%. Good pipeline of products. Good R & D budget.

BUY

Has a new drug, competing with Prozac. Also into biotechs, making good diversification.

Showing 91 to 105 of 109 entries

Most Recent Experts

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Lyle Stein

Forvest Global Wealth Management

Andrew Pink

LDIC

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Greg Newman

Scotia Wealth Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

GlaxoSmithKline PLC (GSK)